Prevalence and Impact of Fatty Liver Disease in Adult Deceased Liver Transplant Donors: Metabolic‐Associated Fatty Liver Disease or Nonalcoholic Fatty Liver Disease?
| Autor: | Ken Liu, Geoffrey W. McCaughan, Susan Virtue, Claire West, Keval Pandya |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
medicine.medical_specialty medicine.medical_treatment Liver transplantation Gastroenterology Liver disease Insulin resistance Non-alcoholic Fatty Liver Disease Risk Factors Diabetes mellitus Internal medicine Nonalcoholic fatty liver disease Prevalence Humans Medicine Prediabetes Transplantation Hepatology business.industry Fatty liver nutritional and metabolic diseases medicine.disease Tissue Donors Liver Transplantation Surgery Steatosis business |
| Zdroj: | Liver Transplantation. 27:1498-1501 |
| ISSN: | 1527-6473 1527-6465 |
| Popis: | Donor hepatic steatosis is associated with worse post-liver transplant (LT) outcomes, especially when >30%(1). Such donors usually have non-alcoholic fatty liver disease (NAFLD) which is defined as fatty liver (hepatic steatosis >5%) without excessive alcohol consumption (>210g/week for men, >140g/week for women) or concomitant liver disease. Recently, international consensus have proposed that the term NAFLD be replaced by metabolic-associated liver disease (MAFLD)(2). New criteria define MAFLD as fatty liver together with the presence of metabolic conditions (i.e. type 2 diabetes mellitus, elevated ethnicity-specific body mass index (BMI), or at least two of: elevated waist circumference, hypertension, dyslipidemia, prediabetes, and/or insulin resistance)(2). We know these metabolic variables such as raised BMI and diabetes mellitus in a donor also contribute to graft marginality(1, 3). We examined whether a biopsy-proven diagnosis of NAFLD or MAFLD in a liver donor impacted on outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text